NCT04068103 2025-05-07
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NRG Oncology
Phase 2/3 Active not recruiting
NRG Oncology
Tyme, Inc
Bristol-Myers Squibb
University of California, San Francisco
AstraZeneca